Yong-Fang Shi

No ORCID on file · 1 paper in corpus · active 2024

Study types

  • other 1

Condition tags

  • endometriosis 1
other 2024
Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system
Expert opinion on drug safety ·doi:10.1080/14740338.2024.2351451

OBJECTIVE: Elagolix is approved for the treatment of moderate-to-severe pain associated with endometriosis. However, the long-term safety of elagolix in a large sample of real-world patients is unknown. METHODS: The U.S. Food and Drug Admi…